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Abstract: The standardized antimicrobial administration ratio (SAAR) is a novel antimicrobial
stewardship metric that compares actual to expected antimicrobial use (AU). This prospective cohort
study examines the utility of SAAR reporting and inter-facility comparisons as a motivational tool
to improve overall and broad-spectrum AU within a three-hospital healthcare system. Transparent
inter-facility comparisons were deployed during system-wide antimicrobial stewardship meetings
beginning in October 2017. Stakeholders were advised to interpret the results to foster competition
and incorporate SAAR data into focused antimicrobial stewardship interventions. Student’s t-test
was used to compare mean SAARs in the pre- (July 2017 through October 2017) and post-intervention
periods (November 2017 through June 2019). The mean pre-intervention SAARs for hospitals A, B,
and C were 0.69, 1.09, and 0.60, respectively. Hospital B experienced significant reductions in SAAR
for overall AU (from 1.09 to 0.83; p < 0.001), broad-spectrum antimicrobials used for hospital-onset
infections (from 1.36 to 0.81; p < 0.001), and agents used for resistant gram-positive infections in
the intensive care units (from 1.27 to 0.72; p < 0.001) after the interventions. The alignment of the
SAAR across the health-system and sustained reduction in overall and broad-spectrum AU through
implementation of inter-facility comparisons demonstrate the utility in the motivational application
of this antimicrobial use metric.
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1. Introduction
Antimicrobial stewardship programs (ASPs) have long sought a standardized method
for benchmarking antimicrobial use, allowing comparative antimicrobial stewardship metrics between hospitals and assessment of the effectiveness of targeted interventions [1–3].
Traditional facility-specific antimicrobial use metrics include days of therapy, defined daily
dose, and antimicrobial cost [4]. Large healthcare systems may be able to internally develop
a robust approach to antimicrobial use benchmarking [5]. However, the utility of these tools
may be limited in smaller healthcare systems and community hospitals. In response to this
need, the Centers for Disease Control and Prevention (CDC) National Healthcare Safety
Network (NHSN) introduced the standardized antimicrobial administration ratio (SAAR)
as a metric included in the antimicrobial use option [6]. The primary objective of the
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antimicrobial use option is to facilitate risk-adjusted inter- and intra-facility antimicrobial
use benchmarking using facility-reported data and the provision of a facility-specific SAAR.
The SAAR is a novel, NHSN-developed antimicrobial stewardship metric that compares
observed to predicted antimicrobial use. The SAAR was first provided to participants in
the antimicrobial use option in 2015. Initially based on models developed and applied to
nationally aggregated 2014 adult and pediatric antimicrobial use data, the models used
to provide the SAAR have since been updated, using 2017 adult and pediatric data [7].
The SAAR is provided for overall antimicrobial use and specific patient care locations and
antimicrobial categories. An SAAR statistically greater than one indicates more antimicrobial use than expected, while an SAAR statistically less than one indicates less antimicrobial
use than expected. When interpreting the SAAR, facilities should be aware of its limitations.
The models used currently do not reflect expected antimicrobial use based on the case-mix
index or infectious disease burden [7]. In addition, the data provided are highly dependent
on the accuracy of the facility-reported data. The NHSN provides resources for facilities in
order to educate and encourage internal validation of data submitted to the antimicrobial
use option. Lastly, facilities should be aware of potential seasonal variation in the SAAR [8].
Despite these limitations, the SAAR is considered the most direct metric for the measurement of antimicrobial stewardship performance [9]. To encourage antimicrobial use option
participation, the CDC specifies tracking of antimicrobial use and reporting to NHSN as a
priority to achieve the core elements of hospital antibiotic stewardship programs [10].
The value of antimicrobial use participation for ASPs has been previously demonstrated [11–16]. The present literature describes the utility of the SAAR as an identifier of
outlier patient care areas and antimicrobial categories requiring additional ASP support
and as a metric to measure the impact of targeted interventions [11–14]. The impact of
transparent distribution of the SAAR and inter-facility comparisons within a multi-hospital
health-system to motivate local providers and ASP leads has not been previously described.
This before and after prospective cohort study evaluates the impact of the SAAR as a
motivational tool on improving overall and broad-spectrum antimicrobial use across a
three-hospital healthcare system.
2. Materials and Methods
2.1. Setting
This study was conducted at three Prisma Health—Midlands hospitals in South
Carolina, USA that varied in bed capacity and patients’ characteristics. These hospitals
provide a variety of medical, surgical, and subspecialty services to patients in the Midlands
of South Carolina. The ASP consists of an infectious diseases physician and pharmacist
leads in each hospital who meet regularly to discuss issues related to antimicrobial use as
well as develop and sustain focused antimicrobial stewardship interventions. Participation
of Prisma Health—Midlands in NHSN’s antimicrobial use option began in July 2017.
Prior to participating in the antimicrobial use option, the ASP used locally generated
metrics, such as days of therapy, to deploy targeted interventions to optimize antimicrobial
use through syndrome-specific and prospective audit and feedback interventions [17].
2.2. Study Design and Definitions
This before and after prospective cohort study examines the impact of the motivational application of the SAAR through characterizing SAAR trends following transparent
inter-facility comparisons. The pre-intervention period included SAARs from July 2017
through October 2017 and the post-intervention period included SAARs from November
2017 through June 2019. Antimicrobials were categorized according to NHSN definitions.
Antibacterial agents used predominantly for hospital-onset infections (broad-spectrum
agents) included anti-pseudomonal beta-lactams (including carbapenems) and intravenous
aminoglycosides. Antibacterial agents predominantly used for resistant gram-positive infections included vancomycin, daptomycin, lipoglycopeptides, ceftaroline, oxazolidinones,
and quinupristin/dalfopristin [9].
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2.3. Motivational Tools
Starting in October 2017, the SAAR was reported by the ASP at inter-professional
system-wide antimicrobial subcommittee meetings. Physicians, infection preventionists,
microbiology personnel, and pharmacists across the healthcare system were invited to
attend. In addition to providing detailed SAARs for patient care locations and antimicrobial
categories, the reports included inter-facility comparisons for the three hospitals in the
system (hospitals A, B, and C) in order to highlight incongruities across the healthcare
system and motivate key players of outlier patient care areas. Healthy competition among
the hospitals was fostered. Pharmacists and physicians were encouraged to use the SAAR
to inform targeted antimicrobial stewardship initiatives within their respective facility
with ASP support. To further motivate key players, associations between unnecessary
broad-spectrum agents and undesired clinical outcomes were highlighted, such as nephrotoxicity, Clostridioides difficile infection, and antimicrobial resistance using local data when
available [18,19]. During subsequent system-wide meetings, the SAAR data were shared
quarterly to provide updates and inform on the progress of targeted interventions.
2.4. Targeted Stewardship Interventions
Using the pre-intervention SAAR report shared in October 2017, facilities enhanced
the implementation of existing interventions to improve antimicrobial use with the goal of
reducing the facility and specific patient-care location SAAR values. The targeted interventions involved electronic alerts to facilitate prospective audit and feedback for commonly
used anti-pseudomonal beta-lactams (piperacillin/tazobactam, cefepime, and meropenem)
and vancomycin in intensive care units (ICUs). These alerts fired upon a targeted antimicrobial order being active for >48 h. A locally derived clinical risk score for prediction
of the probability of infections due to Pseudomonas aeruginosa was utilized to guide early
de-escalation of anti-pseudomonal therapy in low-risk patients [20]. Clinicians were encouraged to use nasal methicillin-resistant Staphylococcus aureus (MRSA) polymerase chain
reaction (PCR) to facilitate early discontinuation of anti-MRSA agents in hospitalized
patients with pneumonia. Lastly, a focused initiative to improve the partnership and
bidirectional education was deployed by daily (Monday through Friday) multidisciplinary
rounds in the ICUs, including critical care specialists and antimicrobial stewardship pharmacists. All these existing interventions were simultaneously started in all three hospitals
prior to the beginning of the study, as previously described [17]. Implementation of these
interventions was further emphasized after sharing of the SAAR reports in October 2017.
2.5. Data Analysis
A Student’s t-test was used to compare the mean SAAR in pre-intervention and
post-intervention periods for all antimicrobials and specific patient care locations and
antimicrobial categories within each hospital. JMP Pro (version 13.0, SAS Institute Inc.,
Cary, NC, USA) was used for statistical analysis. The level of significance for statistical
testing was defined as 2-sided p < 0.05.
3. Results
The three hospitals maintained consistent participation in the NHSN antimicrobial
use option during the 2-year study period. The mean pre-intervention SAARs for hospitals
A, B, and C were 0.69, 1.09, and 0.60, respectively. Antimicrobial use of broad-spectrum
agents predominantly used for hospital-onset infections and agents used for resistant
gram-positive infections in the ICUs were particularly high in hospital B based on SAARs
of 1.36 and 1.27, respectively (Table 1).
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Table 1. Pre- and post-intervention mean standardized antimicrobial administration ratio (SAAR)
for antimicrobial categories and patient care locations. ICU, intensive care unit.

Table 1. Pre- and post-intervention mean standardized antimicrobial administration ratio (SAAR) for antimicrobial
categories and patient care locations. ICU, intensive care unit. Hospital A
Hospital B
Hospital C

SAAR Category

pHospital
PostHospital B Pre
Post p-Value
Pre C Post p-Value
Value
Pre
Post
p-Value
Pre
Post
p-Value
Pre
Post
p-Value
All agents, all locations
0.69
0.62
0.06
1.09
0.83 <0.001 0.60 0.64
0.69
All agents, all locations Broad-spectrum
0.69
0.62
0.06
1.09
0.83
<0.001
0.60
0.64
0.69
agents used
Broad-spectrum agents used
for hospital-onset
infections,
0.671.360.52 0.81
0.01
1.36
0.81 0.83
<0.001 0.54
0.83 0.54
0.007
for hospital-onset infections,
0.67
0.52
0.01
<0.001
0.007
ICU
ICU
Agents used for resistant Agents used for resistant
0.591.270.64 0.72
0.37
1.27
<0.001 0.60
0.68 0.600.31 0.31
gram-positive infections,gram-positive
0.59
0.64
0.37
<0.001 0.72 0.68
infections,
ICU
SAAR Category

Hospital A

Pre

ICU

A plan was outlined to enhance ASP interventions targeting anti-pseudomonal betaA plan
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There were also significant declines in SAARs for broad-spectrum antimicrobial agents
There were also significant declines in SAARs for broad-spectrum antimicrobial
predominantly used for hospital-onset infections and agents used for resistant gramagents
predominantly used for hospital-onset infections and agents used for resistant
positive infections in the ICUs in hospital B after the interventions (Table 1). The reductions
gram-positive
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the ICUs
inmaintained
hospital Bduring
after the
interventions
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in SAARs for
these two in
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were
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intervention period (Figures 2 and 3).

Pharmacy 2021, 9, 32

5 of 8

Pharmacy2020,
2020,8,
8,xxFOR
FORPEER
PEERREVIEW
REVIEW
Pharmacy

of88
55of

FigureFigure
2. SAAR
SAAR
trends
for broad-spectrum
broad-spectrum
agents
used
for
hospital-onset
infections
in
adult
ICUs.
2. SAAR
trends
for broad-spectrum
agentsused
usedfor
forhospital-onset
hospital-onset infections
inin
adult
ICUs.
Figure
2.
trends
for
agents
infections
adult
ICUs.

3. SAAR
trends
for antimicrobial
agents
used
forresistant
resistant gram-positive
gram-positive
in in
adult
ICUs.
FigureFigure
3. SAAR
SAAR
trends
for antimicrobial
antimicrobial
agents
used
for
resistant
gram-positiveinfections
infections
in adult
adult
ICUs.
Figure
3.
trends
for
agents
used
for
infections
ICUs.

4. Discussion
4. Discussion
Discussion
4.
In this
multi-hospitalhealthcare
healthcare system,
system, reporting
antimicrobial
use use
to NHSN
identiIn this
this
multi-hospital
reporting
antimicrobial
to NHSN
NHSN
idenIn
multi-hospital
healthcare system,
reporting
antimicrobial
use to
idenfied obvious opportunities for improvement in particular patient care locations and specific
tified
obvious
opportunities
for
improvement
in
particular
patient
care
locations
and
spetifiedantimicrobial
obvious opportunities
for improvement
in particular
patient care
and specategories. Application
of the SAAR
as a motivational
toollocations
through transcific antimicrobial
antimicrobial categories. Application
Application of
of the
the SAAR
SAAR as
as aa motivational
motivational tool
tool through
through
cific
parent reportingcategories.
and interfacility comparisons
was followed
by significant reductions
in
transparent
reporting
and
interfacility
comparisons
was
followed
by
significant
reductransparent
reporting
and interfacility
comparisons
was infollowed
byhospital.
significant
reducoverall and
broad-spectrum
antimicrobial
use in the ICUs
the outlier
Encourtionsaging
in overall
overall
and
broad-spectrum
antimicrobial
use in
in the
the ICUs
ICUs
inhealthcare
the outlier
outlier
hospital.
tions
in
and
broad-spectrum
use
in
the
hospital.
healthy
competition
betweenantimicrobial
multiple hospitals
within
a large
system
Encouraging
healthy
competition
between
multiple
hospitals
within
a
large
healthcare
seemed to healthy
enhance competition
the implementation
of existing
multi-faceted
interventions
based
Encouraging
between
multiple
hospitals ASP
within
a large healthcare
primarily
on local
data. These
support existing
literature
demonstrating
the intervenvalue
system
seemed
to enhance
enhance
thefindings
implementation
of existing
existing
multi-faceted
ASP
intervensystem
seemed
to
the
implementation
of
multi-faceted
ASP
of
the
SAAR
as
an
antimicrobial
stewardship
metric
for
the
identification
of
trends
in
tions
based
primarily
on
local
data.
These
findings
support
existing
literature
demonstrattions based primarily on local data. These findings support existing literature demonstratantimicrobial
use
and
opportunities
for
improvement
[9,13–16].
ing the
the value
value of
of the
the SAAR
SAAR as
as an
an antimicrobial
antimicrobial stewardship
stewardship metric
metric for
for the
the identification
identification of
of
ing
The pre-intervention SAAR analysis revealed hospital B as an outlier within the
trends
in
antimicrobial
use
and
opportunities
for
improvement
[9,13–16].
trends
in antimicrobial use and opportunities for improvement [9,13–16].
healthcare system. The higher antimicrobial use in hospital B compared with hospitals A
The pre-intervention
pre-intervention SAAR
SAAR analysis
analysis revealed
revealed hospital
hospital BB as
as an
an outlier
outlier within
within the
the
The
and C during the first 4 months
of reporting
to the NHSN antimicrobial
use option
was
healthcare
system.
The
higher
antimicrobial
use
in
hospital
B
compared
with
hospitals
A
healthcare
system.
The higher
antimicrobial
in hospital
B compared
hospitals
consistent
with historic
days of
therapy data use
collected
by the local
ASP sincewith
January
2013 A
and(data
C during
during
the
first 44Differences
months of
ofin
reporting
to the
the
NHSN
antimicrobial
use option
option
was
and
C
the
first
months
reporting
to
antimicrobial
use
are not
shown).
antimicrobial
useNHSN
between
the three hospitals
withinwas
consistent
with
historic
days
of
therapy
data
collected
by
the
local
ASP
since
January
2013
the healthcare
systemdays
wereof
previously
attributed
to variations
in hospital
characteristics
consistent
with historic
therapy data
collected
by the local
ASP since
January 2013
and
patient
populations.
However,
the
reality
of
excessive
antimicrobial
use
in
hospital
B
(data
are
not
shown).
Differences
in
antimicrobial
use
between
the
three
hospitals
within
(data are not shown). Differences in antimicrobial use between the three hospitals within
was
more
apparent
when
the
SAAR
data
were
presented
at
the
system-wide
ASP
meeting
in
the
healthcare
system
were
previously
attributed
to
variations
in
hospital
characteristics
the healthcare system were previously attributed to variations in hospital characteristics
and patient
patient populations.
populations. However,
However, the
the reality
reality of
of excessive
excessive antimicrobial
antimicrobial use
use in
in hospital
hospital BB
and
wasmore
moreapparent
apparentwhen
whenthe
theSAAR
SAARdata
datawere
werepresented
presentedat
atthe
thesystem-wide
system-wideASP
ASPmeeting
meeting
was
in
October
2017,
as
the
SAAR
metric
is
based
on
comparisons
of
each
hospital’s
antimiin October 2017, as the SAAR metric is based on comparisons of each hospital’s antimicrobial use to its peer hospitals at the national level. This led to further investigation of

Pharmacy 2021, 9, 32

6 of 8

October 2017, as the SAAR metric is based on comparisons of each hospital’s antimicrobial
use to its peer hospitals at the national level. This led to further investigation of the
potential drivers of increased antimicrobial use. Through analysis of SAARs specific
to antimicrobial categories and patient care locations, ICUs appeared to be the driver
of increased antimicrobial use, specifically broad-spectrum agents predominantly used
for hospital-onset infections and agents used predominantly for resistant gram-positive
infections. Existing targeted interventions were emphasized across the healthcare system,
including local tools to select appropriate empirical antimicrobial therapy and prospective
audit and feedback for select antimicrobials. Periodic sharing of SAAR reports at systemwide antimicrobial stewardship meetings on a quarterly basis likely contributed to the
sustained reduction of the SAAR in hospital B during the pot-intervention period.
Enrollment in the NHSN antimicrobial use option and access to SAAR data allow ASPs
to incorporate a new antimicrobial stewardship metric into data reporting and tracking.
Because the SAAR simplifies antimicrobial use into a ratio comparing actual to expected
use, it is a digestible metric for inter-facility comparisons and communications with general
healthcare providers who may not be familiar with traditional antimicrobial use metrics,
such as days of therapy or defined daily doses. Literature is lacking to guide ASPs on
what SAAR values should be targeted. As the current comparator is aggregated data from
2017, the local ASP aspires to achieve SAARs less than one for overall and broad-spectrum
antimicrobials, assuming a level of maturation in nationwide ASPs over the previous
three years with the inauguration of robust regulatory standards.
The integration of inter-facility comparisons within multi-faceted ASP interventions
expands on the previous literature to suggest that the SAAR may have utility as a motivational tool in addition to its utility as an antimicrobial use metric [7,9]. The study has certain
limitations. Concurrent reporting of inter-facility comparisons and implementation of multiple interventions limits the ability to ascertain the specific impact of each intervention.
However, the confounding effect of multiple interventions was minimized by system-wide
implementation of the interventions in all hospitals rather than targeting hospital B alone.
A reduction in the SAARs for antimicrobial agents predominantly used for hospital-onset
infections in the ICUs was observed in all three hospitals (Table 1). However, hospital B
demonstrated the most drastic reduction in the SAAR for this antimicrobial category as
well as significant reductions in overall antimicrobial use and agents predominantly used
for resistant gram-positive infections in the ICUs. These observations may be an indicator
of the motivational utility of SAAR reporting and inter-facility comparisons. The relatively
short pre-intervention period represents another limitation of this study. Because of the
perceived value of promptly sharing the SAAR data with the healthcare system, it was the
desire of the ASP committee to distribute the information and initiate interventions with
the availability of the data. In addition, antimicrobial use in the 4-month pre-intervention
period was consistent with data previously analyzed across the health-system by the local
ASP prior to participation in the NHSN antimicrobial use option. The study included
SAAR data from three hospitals within one healthcare system. Future studies from larger
healthcare networks would be useful to improve generalizability. The SAAR is a quantitative rather than qualitative antimicrobial stewardship metric. Future studies are needed
to correlate the SAAR with quality of care and clinical outcomes. Finally, the SAAR is
an antimicrobial stewardship metric that is currently available only to hospitals in the
USA. An alternative method for adjustment of antimicrobial use by microbiological burden has been recently proposed and evaluated in a multicenter study in southeastern
USA [9,21]. This novel antimicrobial stewardship metric for adjusted antimicrobial use by
microbiological burden may be applied in other countries as well.
5. Conclusions
The utilization of SAAR reports allowed the identification of opportunities for improvement within specific locations and antimicrobial categories in the healthcare system.
These findings support the motivational utility of the SAAR in reducing excessive antimicro-
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bial use and alignment of the metric across multi-hospital healthcare systems. Transparent
periodic SAAR reporting and inter-facility comparisons with the goal to foster competition
enhance multi-faceted interventions and focus system-wide ASP efforts.
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